JP2021530249A5 - - Google Patents

Info

Publication number
JP2021530249A5
JP2021530249A5 JP2021523582A JP2021523582A JP2021530249A5 JP 2021530249 A5 JP2021530249 A5 JP 2021530249A5 JP 2021523582 A JP2021523582 A JP 2021523582A JP 2021523582 A JP2021523582 A JP 2021523582A JP 2021530249 A5 JP2021530249 A5 JP 2021530249A5
Authority
JP
Japan
Prior art keywords
myxoma virus
myxv
cells
use according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530249A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041700 external-priority patent/WO2020014670A1/en
Publication of JP2021530249A publication Critical patent/JP2021530249A/ja
Publication of JP2021530249A5 publication Critical patent/JP2021530249A5/ja
Pending legal-status Critical Current

Links

JP2021523582A 2018-07-13 2019-07-12 Tnf発現粘液腫ウイルスで癌を処置する方法 Pending JP2021530249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697581P 2018-07-13 2018-07-13
US62/697,581 2018-07-13
PCT/US2019/041700 WO2020014670A1 (en) 2018-07-13 2019-07-12 Methods of treating cancer with tnf expressing myxoma virus

Publications (2)

Publication Number Publication Date
JP2021530249A JP2021530249A (ja) 2021-11-11
JP2021530249A5 true JP2021530249A5 (cg-RX-API-DMAC7.html) 2022-07-19

Family

ID=69141734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523582A Pending JP2021530249A (ja) 2018-07-13 2019-07-12 Tnf発現粘液腫ウイルスで癌を処置する方法

Country Status (12)

Country Link
US (1) US12257278B2 (cg-RX-API-DMAC7.html)
EP (1) EP3820491A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021530249A (cg-RX-API-DMAC7.html)
KR (1) KR20210031485A (cg-RX-API-DMAC7.html)
CN (1) CN112996908A (cg-RX-API-DMAC7.html)
AU (1) AU2019300162A1 (cg-RX-API-DMAC7.html)
CA (1) CA3106202A1 (cg-RX-API-DMAC7.html)
IL (1) IL280060A (cg-RX-API-DMAC7.html)
MX (1) MX2021000505A (cg-RX-API-DMAC7.html)
SG (1) SG11202100305SA (cg-RX-API-DMAC7.html)
TW (1) TW202024326A (cg-RX-API-DMAC7.html)
WO (1) WO2020014670A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
EP3946373A4 (en) * 2019-03-28 2023-01-11 Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University FAST-PP14-EXPRESSING ONCOLYTIC MYXOMAVIRUS FOR TREATMENT OF BLOOD CANCER
CN114615988A (zh) * 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
US20240091284A1 (en) * 2019-10-10 2024-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
JP2024508920A (ja) * 2021-03-01 2024-02-28 オンコミクス セラピューティクス,インク. 多武装の粘液腫ウイルス

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
WO2007143545A2 (en) * 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments
WO2011156273A1 (en) 2010-06-06 2011-12-15 Mount Sinai School Of Medicine Recombinant rna viruses and uses thereof
EP2717887B1 (en) * 2011-06-09 2017-12-27 University of Florida Research Foundation, Inc. Methods for treating or preventing graft versus host disease
ES2895977T3 (es) * 2013-11-28 2022-02-23 Bavarian Nordic As Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus
AU2016313969B2 (en) 2015-06-19 2021-12-23 Sillajen, Inc. Compositions and methods for viral embolization
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
BR112021002639A2 (pt) 2018-08-16 2021-05-11 Musc Foundation For Research Development vírus recombinantes do mixoma e usos dos mesmos
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
EP3946373A4 (en) 2019-03-28 2023-01-11 Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University FAST-PP14-EXPRESSING ONCOLYTIC MYXOMAVIRUS FOR TREATMENT OF BLOOD CANCER
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Similar Documents

Publication Publication Date Title
Guo et al. Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives
Bartlett et al. Oncolytic viruses as therapeutic cancer vaccines
Marchini et al. Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade
Nguyen et al. Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer
Liu et al. Gene therapy progress and prospects cancer: oncolytic viruses
Francescangeli et al. COVID-19–Induced modifications in the tumor microenvironment: do they affect cancer reawakening and metastatic relapse?
Wu et al. The role of pyroptosis in modulating the tumor immune microenvironment
Zou et al. Combining of oncolytic virotherapy and other immunotherapeutic approaches in cancer: a powerful functionalization tactic
Zhu et al. Recent advances in oncolytic virus therapy for hepatocellular carcinoma
Sanchala et al. Oncolytic herpes simplex viral therapy: a stride toward selective targeting of cancer cells
Forbes et al. Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses
CN110325200B (zh) 治疗剂及其在治疗肿瘤和/或癌症的药物中的应用
de la Nava et al. Immunovirotherapy for pediatric solid tumors: A promising treatment that is becoming a reality
Alvarez-Breckenridge et al. Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection
Moehler et al. Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1
Gao et al. Targeting p53 for neuroinflammation: New therapeutic strategies in ischemic stroke
Hu et al. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them
Huang et al. Innate immunity and immunotherapy for hemorrhagic shock
Svyatchenko et al. Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines
Sheik Targeting key transcription factors in hepatocellular carcinoma
De Silva et al. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses
Shao et al. Oncolytic virotherapy in peritoneal metastasis gastric cancer: the challenges and achievements
Chou et al. In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles
Franks et al. The role of natural killer cells in oncolytic virotherapy: friends or foes?
Haidar Oncolytic viruses: from basics to challenges to innovation